tbuckley/cabot-search huggingface dataset:
Long-term Risks and Benefits of Bariatric Surgery
Authors: Bruce M. Wolfe, Steven H. Belle
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Prevention Trial With Tamoxifen Being Considered
Authors: Kara Smigel
Journal: JNCI Journal of the National Cancer Institute (1990)

Journal Article Prevention Trial With Tamoxifen Being Considered Get access Kara Smigel Kara Smigel Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 22, 21 November 1990, Pages 1737–1738, https://doi.org/10.1093/jnci/82.22.1737 Published: 21 November 1990
Preclinical evaluation of an immunotherapeutic peptide comprising 7 T-cell determinants of Cry j 1 and Cry j 2, the major Japanese cedar pollen allergens
Authors: Kazuki Hirahara, Toru Tatsuta, Toshiro Takatori, Masahiko Ohtsuki, Hideyo Kirinaka, Junko Kawaguchi, Nobufusa Serizawa, Yoshifumi Taniguchi, Saburo Saito, Masahiro Sakaguchi
Journal: Journal of Allergy and Clinical Immunology (2001)
Anaphylactoid Reaction After Chymacort Ointment
Authors: R. Pippen
Journal: BMJ (1966)

BMRNA, do we interfere with the natural forces com- bating a virus invasion in our patients ?To relieve discomfort ?But the fever relapses, the patient vomits from chemical gastritis; septic throats, ears, sinuses, and chests are common sequelae with aspirin treatment.Even the simple cold cannot be endured with- out resort to an increasingly ominous array of short-cut suppressive drugs, which cause the colds to abort, relapse, and abort again until, when the reservoirs of virus have swollen to overwhelming proportions in the host, a major febrile "influenza " develops.Anyone who is interested in the natural history of respiratory virus illness, and the host capacity to deal with it effectively, has only to follow Dr. Bowie's example by ceas- ing to use antipyretic drugs.I have used garlic oil, soda mints, sulphur and glucose, and oil of violets as placebos for five years in persons of all ages from birth up to 50.During this period most patients, especially the parents of children, have learned the simple trick of avoiding aspirin and are very happy with the result.We don't need anal- gesics very often, because tonsillitis and otitis
Preimplantation Genetic Diagnosis for Cancer Syndromes
Authors: Kenneth Offit, Michal Sagi, Karen Hurley
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dual Modulation of Cell Survival and Cell Death by β2-Adrenergic Gi and Gs Signaling in Adult Mouse Cardiac Myocytes
Authors: Wei-Zhong Zhu, Ming Zheng, Brian Kobilka, Rui-Ping Xiao
Journal: Circulation (2000)

There is considerable debate about the choice of intravenous platelet glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention, after a meta-analysis of 7 trials and 16,770 patients has shown a 38% reduction in death or non-fatal MI 30 days after the index procedure.At 149 hospitals in 18 countries throughout North America, Europe and Australia, 4810 patients were randomized between 12/30/99 and 8/25/00 and treated with either tirofiban or abciximab on a double-blind, double dummy basis.Clopidogrel and aspirin were administered preprocedurally, along with a 70 U/kg intravenous heparin bolus.The dose of tirofiban was 10 mcg/kg bolus and 0.15 mcg/kg/min infusion for 18 -24 hrs; for abciximab it was 0.25 mcg/kg bolus and 0.125 mcg/kg/min (max 10 mcg/min) infusion.Patients qualified by having suitable anatomy for "intent-to-stent" lesions addressed by percutaneous revascularization, and were not with evolving ST-elevation MI or with serum creatinine Ͼ2.5 mg/dl.The primary endpoint is 30 death or non-fatal MI and the trial has Ͼ80% power to determine non-inferiority for tirofiban with an expected event rate in the control (abciximab) group of 5.3% based on the EPISTENT trial.The primary endpoint data will be presented along with the key subgroups such as diabetics.Follow-up data for the trial to 1 year will also be performed.
Severe Hypermetabolism with Primary Abnormality of Skeletal Muscle Mitochondria
Authors: NAJEEB ABU HAYDAR
Journal: Annals of Internal Medicine (1971)

A 19-year-old woman with features of extreme hypermetabolism, believed to have the second reported case of Luft's syndrome, was studied. The clinical manifestations almost duplicate those reported by Luft. Electron-micrographic and biochemical data indicate that the immediate factor responsible is a large overgrowth of skeletal muscle mitochondria, anatomically bizarre and functionally characterized by excessive respiration and uncoupling of oxidative phosphorylation. A defective protein content or structure of mitochondria may be responsible for most of the functional defects. Chloramphenicol produced clinical improvement, apparently largely as a result of depression of synthesis of abnormal mitochondria. All findings are best explained by the concomitant operation in skeletal muscle of a pseudoneoplastic, uncoupled, increased mass of abnormal mitochondria and a reduced mass of mitochondria functioning normally. Chloramphenicol has a differential effect on the former. Certain differences between the "coupling" data of Luft and ours and certain aspects of the "coupling" response to chloramphenicol remain unexplained, as does the ultimate etiology of the mitochondrial disease.
Current Therapy 1980: Latest Approved Methods of Treatment for the Practicing Physician
Authors: William R. Best
Journal: JAMA (1980)

This is the latest edition of a compendium that has followed the same format for the past 32 years. Each year, the editor and consulting editors assign more than 280 diseases to a new panel of experts, none of whom covers more than one condition. Thus, each topic is new each year, giving the personal practices and preferences of the current authority. Emphasis may differ from the previous year, but a strong thread of recommendations is carried throughout. The average length of articles is 3 1/2 pages. Emphasis in each is primarily on treatment, including the general approach to management, drug therapy, surgery, and radiology. The old and the new are considered thoughtfully, and specific recommendations are usually given. Prevention is often emphasized. No references are cited. The breadth and depth of coverage are appropriate to the problems of the generalist or the specialist outside of his usual realm. It
Abstract C11: Using GCP to improve initial response to androgen deprivation in prostate cancer
Authors: Benjamin A. Mooso, Maria Mudryj, Ralph W. deVere White, Paramita M. Ghosh, Rosalinda M. Savoy, Jean P. Cheung, Ruth L. Vinall, Clifford G. Tepper, Yu Wang, Salma Siddiqui, Roble G. Bedolla, Margarita Mikhailova
Journal: Cancer Research (2012)

Abstract Recurrent prostate cancer (PCa) is treated with androgen deprivation therapy (ADT, chemical castration), but patients on this treatment frequently relapse, indicative of the advent of castration resistant prostate cancer (CRPC). Due to the multifocal nature of the disease, any one treatment may not affect all pathways altered in CRPC; therefore, we set out to delay CRPC by increasing the apoptotic rate during ADT. We previously published that Filamin A (FlnA) is localized to the nucleus in androgen-dependent cells, whereas its expression is lost from the nucleus in CRPC. Restoration of FlnA nuclear expression induced apoptosis in the absence of androgens. We now show that genistein combined polysaccharide (GCP), a combination of isoflavones, can induce FlnA translocation to the nucleus. GCP and its main component genistein previously failed to prevent progression in pre-prostatectomy patients with low-grade PCa. However, our new data, both in vitro and in an animal model, show that GCP impedes relapse following castration, and induces apoptosis in PCa cells undergoing ADT, by promoting FlnA cleavage and nuclear translocation. Investigation of the mechanism of GCP's effects on FlnA showed that ADT phosphorylates FlnA and prevents its cleavage, whereas GCP inhibits FlnA phosphorylation, thereby promoting its cleavage and nuclear translocation. Additional data show that nuclear localization of FlnA induces apoptosis during ADT by preventing androgen receptor (AR) stabilization and by suppression of the ErbB3/PI3K/Akt axis. Taken together, our results identify GCP as a putative therapeutic module to prolong the effectiveness of ADT in patients with metastatic prostate cancer. Citation Format: Benjamin A. Mooso, Maria Mudryj, Ralph W. deVere White, Paramita M. Ghosh, Rosalinda M. Savoy, Jean P. Cheung, Ruth L. Vinall, Clifford G. Tepper, Yu Wang, Salma Siddiqui, Roble G. Bedolla, Margarita Mikhailova. Using GCP to improve initial response to androgen deprivation in prostate cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Prostate Cancer Research; 2012 Feb 6-9; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2012;72(4 Suppl):Abstract nr C11.
Chest Pain Following Aortocoronary Bypass Graft
Authors: Gary G. Winzelberg
Journal: JAMA (1982)

<h3>History</h3> A 48-year-old man underwent three-vessel aortocoronary bypass graft for unstable angina and high-grade occlusive coronary artery disease. Postoperatively, the patient did well and had total relief of pain. Use of all cardiac medication was discontinued. He was discharged after ten days. Four weeks later he was readmitted to the hospital with recurrent chest pain. Physical examination revealed low-grade fever, with temperature of 38 °C. The lungs were clear and cardiovascular examination results were normal. An ECG demonstrated minor diffuse ST-T wave changes. Serial creatinine phosphokinase (MB isoenzymes) and SGOT measurements were within nomal levels. A computed tomogram (CT) of the chest (Fig 1) was obtained. <h3>Diagnosis</h3> Postpericardiotomy syndrome with patent aortocoronary bypass grafts. Figure 2 shows a CT section taken at the level of the aortocoronary bypass grafts after infusion of contrast material. Patent grafts to the right, left anterior descending, and circumflex coronary arteries are clearly seen as
Clinical Lecture on Antiseptic Osteotomy
Authors: W. Macewen
Journal: BMJ (1879)

GENTLEMEN,-Having at present in my wards ten persons who have been subjected to osteotomy for various deformities, and on whom sixteen osteotomies have been performed, I consider it a suitable time to direct your attention to this subject; and in this morning's remarks reference will be made, among other points, to the following: the age suitable for such operations; the kind of instruments employed, and how to use them; and the surgical anatomy of the site selected for my operation of simple femoral incision in genu valgum.In a lecture recently published, I stated that t-he most suitable age for operating in knock-knee and bow-leg was from eight to about twenty years.On several occasions, I refused to operate on those above twenty.Since that time, however, as those of you who attend my wards have seen, four patients have been operated on by me over twenty years; two of them having knock-knee, one a bow-leg, and one an angular ankylosis of the knee-joint; their ages being twenty-two, twenty- six, twenty-seven, and thirty-two years respectively.In the first case, a double osteotomy, the temperature registered rather more than one degree above normal during the first two nights, but all the morning and all the subsequent evening temperatures were normal.In the * The word "osteotome" has been previously applied to two articles-a chainsaw-and by the French to a pair of bone-forceps.The term as designating these articles has now fallen into disuetude.
The Use of the Direct Eosinophil Count in the Diagnosis and Treatment of Waterhouse-Friderichsen Syndrome
Authors: W. W. Faloon, R. W. Reynolds, R. T. Beebe
Journal: New England Journal of Medicine (1950)

THE use of the direct eosinophil count in the estimation of adrenocortical function was first described by Forsham and his co-workers.1 It was suggested that such a procedure might be of value in determining adrenocortical activity in various pathologic conditions. The authors have found that secretion of 11-oxysteroid compounds by the adrenal cortex following stimulation by pituitary adrenocorticotrophic hormone (ACTH) results in a decrease in the eosinophil count. Similarly, under conditions of stress when there is adequate adrenocortical reserve the eosinophil count has been shown to fall. Thorn2 has suggested that the eosinophil count could be used in the diagnosis . . .
Antilymphocytic Serum in Experimental Allergic Encephalomyelitis
Authors: E. J. Field
Journal: BMJ (1969)

Antilymphocytic and antithymic sera (raised in rabbits) are highly potent in preventing or alleviating experimental allergic encephalomyelitis in guinea-pigs. Good results are obtained when treatment is begun as late as 10 days after challenge. No protracted disease was seen from the use of antilymphocytic serum. Attempts to use this serum therapeutically once the disease was clinically established gave equivocal results. Antilymphocytic serum appears to have a non-specific stressor effect as well as its specific action, and possibly this adrenocorticotrophic-hormone (antiphlogistic) effect may ameliorate a developing encephalitis. The presence of an antimacrophagic factor in antilymphocytic serum may be important in increasing local reaction to injection of the serum and perhaps also in diminishing the appearance of haematogenous elements in the nervous lesions.
An Address Delivered at the Opening of the Section of Therapeutics
Authors: W. V. Snow
Journal: BMJ (1891)

and not by destroying or starving the invading germ; and this is never more true or more obvious than in children.If I might be inclined to qualify what I lhave said even ever so little as regards adult life, and perhaps more so during the period of its decline thaii for any other, I believe it to be absolute for the periods of growth and development, and I shall venture to say that in the diseases of children tbere is nothing that gives the smallest counteniance to specialism; they are rather to be considered as the grammar of disease.
Selective long-term elimination of natural killer cells in vivo by an anti-interleukin 2 receptor beta chain monoclonal antibody in mice.
Authors: T Tanaka, F Kitamura, Y Nagasaka, K Kuida, H Suwa, M Miyasaka
Journal: The Journal of Experimental Medicine (1993)

The interleukin 2 receptor beta chain (IL-2R beta) is preferentially expressed in natural killer (NK) cells, but is not detected in a majority of resting T and B cells. We recently established a novel monoclonal antibody (mAb) to murine IL-2R beta and examined in vivo the effect of the mAb in mice. We found that intraperitoneal injection of the anti-IL-2R beta mAb into adult mice resulted in a selective in vivo elimination of splenic NK function in various mouse strains. The reduction of NK cell function is associated with complete disappearance of NK1.1+ cells in C57BL/6 mice. Other lymphocyte subsets in the thymus and spleen were uncompromised. T cell function was not affected by the mAb treatment as judged by allogeneic cytotoxic T cell induction. The single injection of anti-IL-2R beta mAb caused a long-term elimination of splenic NK cells, lasting for at least 5 wk. We also found that NK and/or NK precursor cells become susceptible to the mAb treatment only after birth, suggesting that functional maturation of NK cells in terms of IL-2R beta expression is a later event in the course of NK cell development. The use of the anti-IL-2R beta mAb will be useful in defining the physiological role of NK cells in host defense as well as dissecting their developmental pathway in vivo.
760-6 Initial In-Vivo and In-Vitro Testing of an Ultrasound-Guided Directional Coronary Atherectomy Catheter
Authors: Andrew I. Maclsaac, Paul G. Yock, Peter J. Fitzgerald, Stephen N. Oesterle, Robert S. Schwartz, Stuart T. Higano, Joseph P. Carrozza, Donald S. Baim, James Vetter, Tomoaki Hinohara
Journal: Journal of the American College of Cardiology (1995)
Review of<i>The Comatose Patient</i>
Authors: Stephen A. Figueroa
Journal: JAMA Neurology (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Lentiviral Vector Design for Multiple shRNA Expression and Durable HIV-1 Inhibition
Authors: Olivier ter Brake, Karen 't Hooft, Ying Poi Liu, Mireille Centlivre, Karin Jasmijn von Eije, Ben Berkhout
Journal: Molecular Therapy (2008)

Human immunodeficiency virus type 1 (HIV-1) replication in T cells can be inhibited by RNA interference (RNAi) through short hairpin RNA (shRNA) expression from a lentiviral vector. However, for the development of a durable RNAi-based gene therapy against HIV-1, multiple shRNAs need to be expressed simultaneously in order to avoid viral escape. In this study, we tested a multiple shRNA expression strategy for different shRNAs using repeated promoters in a lentiviral vector. Although highly effective in co-transfection experiments, a markedly reduced activity of each expressed shRNA was observed in transduced cells. We found that this reduced activity was due to recombination of the expression cassette repeat sequences during the transduction of the lentiviral vector, which resulted in deletions of one or multiple cassettes. To avoid recombination, we tested different promoters for multiple shRNA expression. We compared the activity of the human polymerase III promoters U6, H1, and 7SK and the polymerase II U1 promoter. Activities of these promoters were similar, irrespective of which shRNA was expressed. We showed that these four expression cassettes can be combined in a single lentiviral vector without causing recombination. Moreover, whereas HIV-1 could escape from a single shRNA, we now show that HIV-1 escape can be prevented when four shRNAs are simultaneously expressed in a cell.
Sclerotherapy continues to undergo evaluation
Authors: Kathryn Simmons
Journal: JAMA (1984)

Findings from the first prospective, controlled study of chronic esophageal sclerotherapy from the United States have become available. Jacob Korula, MD, assistant professor of medicine at the University of Southern California (USC) School of Medicine, Los Angeles, reported at the recent meeting of the American Association for the Study of Liver Diseases in Chicago that sclerotherapy "appears to decrease bleeding risk and transfusion requirements, and to prolong the bleeding-free interval," but it doesn't appear to increase survival. According to Korula, only one other prospective, fully controlled study of intravariceal sclerotherapy has emerged from the field. That one was done in England (<i>Lancet</i>1982;1:124-127). In this country, the treatment has been studied intensely only for the last four to five years. At the time of the meeting, Korula and co-workers at USC's liver unit, Rancho Los Amigos Hospital, Downey, Calif, had treated 120 patients who had portal hypertension: 63 were randomized
Gas Embolism Produced by Hydrogen Peroxide
Authors: Anthony Shaw, Avram Cooperman, Julia Fusco
Journal: New England Journal of Medicine (1967)

HYDROGEN peroxide has come into common usage in the treatment of neonatal intestinal obstruction due to inspissated meconium since Olim and Ciuti1 described its use in 2 cases of meconium ileus in 1954. Although authors over the past ten years have shown that dilute solutions of hydrogen peroxide function well for this purpose when given by enema or through an enterotomy2 3 4 5 only 2 reports suggesting adverse effects of peroxide have appeared, both within the last year.5 6 7 This paper presents clinical and experimental data leading to the conclusion that hydrogen peroxide may be dangerous to the newborn infant in a degree . . .
Organized Thrombus Occluding a Main Pulmonary Artery
Authors: S. T. Laufer, J. D. Gray
Journal: New England Journal of Medicine (1956)

THE number of published cases of obstruction by thrombus in the right or left pulmonary artery is few. Means and Mallory,1 up to 1931, found 5 and added another. The case of Levy, Mayer and Jobard2 and the 2 reported below bring the total to 9.In addition to the apparent rarity of this condition, Levy et al.2 succinctly emphasize its interest: "The cases of pulmonary thrombosis all come as surprises at autopsy — that is to say, the extreme difficulty of diagnosis is due not only to the great rarity of the condition but also to the clinical circumstances . . .